Sharemaestro Newsreel

MaxCyte (NASDAQ:MXCT) Issues Earnings Results

MaxCyte (NASDAQ:MXCT) reported a slight beat on earnings with an adjusted loss of $0.08 per share against an expected $0.09 loss, and revenue of $6.5 million, largely meeting estimates. The company reaffirmed its 2026 revenue guidance of $30 million–$32 million, anticipating instrument placements to …

Mike Kelly makes multiple trades including Abbott Laboratories and Disney stocks

Congressman Mike Kelly recently executed several trades through the Victoria Kelly Trust ICA, including selling stocks from Abbott Laboratories and The Walt Disney Company, each valued between $1,001 and $15,000. He also sold Pepsico, Inc. stocks worth $15,001 to $50,000. Additionally, Kelly purchased government …

Haemonetics Corp (HAE) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 77/100

Haemonetics Corp (HAE) shares increased by 4.7% to $91.34, approaching its 52-week high, with significant short-term and long-term momentum. Despite this rise, GuruFocus's GF Value™ indicates the stock is overvalued by 7.6% compared to its estimate of $84.90, suggesting no margin of safety for …

Treace Medical Concepts (TMCI) officer disposes shares for tax or exercise costs

Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts (TMCI), reported a Form 4 transaction indicating the disposition of 9,814 shares of common stock. These shares were delivered or withheld to cover exercise price or tax liability. Following this transaction, Scanlan directly holds …

Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer

Cytek Biosciences (CTKB) has granted new equity awards to its Chief Legal Officer and Secretary, Ilan Feuchtwang. These awards include 241,416 Restricted Stock Units (RSUs) and an option to purchase 127,118 shares of common stock at an exercise price of $4.66 per share. Both …

Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.04 EPS

Lucid Diagnostics (NASDAQ:LUCD) reported a Q2 loss of $0.08 per share, missing analyst estimates by $0.04, despite revenue of $1.47 million which slightly exceeded expectations. Shares rose 1.9% following the announcement but remain near their 12-month low. Insider buying was noted, with Director Dennis …

Earnings call transcript: Sera Prognostics misses Q2 2026 estimates as growth builds

Butterfly Network Deputy General Counsel Nicholas Caezza Sells 10,000 Shares at $9.75 Each

Nicholas Caezza, Deputy General Counsel of Butterfly Network, Inc., sold 10,000 shares of Class A Common Stock on August 11, 2026, at a price of $9.75 per share. Following this transaction, Caezza directly holds 300,307 Class A Common Stock shares. The sale was reported …

LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record …

Lumexa Imaging Holdings Reports Q2 2026 Financial Results in SEC 8-K Filing

Lumexa Imaging Holdings, Inc. filed an 8-K report with the SEC on August 12, 2026, announcing its financial results for the quarter ended June 30, 2026. The report includes a press release (Exhibit 99.1) detailing the results of operations and financial condition, as well …

Sera Prognostics earnings missed by $0.03, revenue fell short of estimates

Accuray names two executives to lead transformation efforts

Accuray Incorporated has announced the appointment of Todd Brown as Senior Vice President for a new Enterprise Performance Optimization organization and Sofiane Laoussadi as Senior Vice President, Global Services & Solutions. These appointments are part of the company's "Transformation Phase II" priorities, aimed at …

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

AxoGen (NASDAQ:AXGN) EVP Marc Began Sells 67,500 Shares of Stock

AxoGen EVP Marc Began sold 67,500 shares of company stock for approximately $3.20 million, reducing his direct holdings by over 57%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, AxoGen shares rose, nearing their 52-week high, and …

AxoGen (NASDAQ:AXGN) Director Sells $646,552.26 in Stock

AxoGen Director Amy McBride Wendell sold 13,353 shares of AXGN stock for over $646,000, reducing her total holdings by 11.01%. This sale occurred under a pre-arranged Rule 10b5-1 plan, and comes as AxoGen shares traded up 2.5% to $49.67, near their 52-week high, following …

Accuray (NASDAQ: ARAY) seeks approval for $55M recapitalization, dilution and reverse split

Accuray (NASDAQ: ARAY) is seeking stockholder approval for a significant financing and recapitalization plan, including issuing $55 million in Series A Convertible Preferred Stock and warrants, and a reverse stock split. The plan aims to strengthen liquidity, reduce leverage, and achieve Nasdaq compliance, but …

FEED Looks 91.4% Undervalued on GF Value™ Despite Distressed Fundamentals

ENvue Medical Inc (NASDAQ: FEED) announced a $50 million equity facility to enhance its ENvue feeding tube navigation system and explore new technologies, despite a nearly 10% pre-market share drop. The company's GF Value™ suggests it is 91.4% undervalued, yet its GF Score™ of …

Earnings call transcript: QT Imaging misses Q2 2026 profit forecast

QT Imaging (QTI) reported strong Q2 2026 financial results, with revenue increasing by 103% year-over-year to $7.4 million, driven by higher scanner shipments. The company affirmed its 2026 revenue guidance of approximately $39 million, more than double the 2025 revenue, and is expanding its …

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

Boston Scientific's CEO Bought $9M of His Own Stock

Boston Scientific's CEO, Michael Mahoney, purchased approximately $9 million of his company's stock, with two directors also buying shares and no 10b5-1 plan in place. Additionally, CoStar founder-CEO Andrew Florance bought about $2.5 million of his own stock. The article also notes that President …

Treace Medical Concepts (TMCI) CEO John T. Treace reports 19.2% beneficial stake

John T. Treace, CEO of Treace Medical Concepts, has filed an amended Schedule 13G indicating a 19.2% beneficial ownership stake in the company, totaling 12,530,959 shares. This ownership includes direct holdings, shares in family trusts, his spouse's holdings, and stock options exercisable within 60 …

Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health …

Tactile Systems Technology (TCMD): Morgan Stanley trims stake to about 3.7%

Morgan Stanley and its affiliate, Morgan Stanley Capital Services LLC, have reduced their beneficial ownership in Tactile Systems Technology Inc. (TCMD). Morgan Stanley now holds 3.7% of TCMD common stock, while Morgan Stanley Capital Services LLC holds 3.5%, with both entities reporting that they …

Tactile Systems Technology (NASDAQ:TCMD) CEO Sells $323,192.32 in Stock

Tactile Systems Technology CEO Sheri Louise Dodd sold 10,978 shares of the company's stock for $323,192.32 to cover tax obligations from vested equity awards, reducing her direct ownership by 4.5%. The company recently reported strong quarterly earnings of $0.34 EPS, surpassing analyst estimates, and …

STERIS (NYSE:STE) Director Sells $956,795.24 in Stock

STERIS (NYSE:STE) Director Mohsen Sohi sold 4,058 shares of the company's stock for a total of $956,795.24, reducing his direct holdings by 14.31% to 24,305 shares. This transaction followed the company's strong earnings report, where STERIS beat analyst EPS estimates and saw revenue rise …

908 Devices (MASS) director Brown sells 17,800 shares in Rule 10b5-1 trades

908 Devices Inc. director Christopher D. Brown sold a total of 17,800 shares of common stock in two open-market transactions on August 10 and August 11, 2026. These sales, executed under a Rule 10b5-1 trading plan adopted in November 2025, involved weighted average prices …

908 Devices (MASS) CEO Knopp sells 149K shares, reports 541K held via trust

Kevin J. Knopp, President and CEO of 908 Devices Inc. (MASS), reported selling 149,013 shares of common stock between August 10 and 12, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices ranging from $9.06 to $10.16 per share. …

Nexalin Technology (NXL) flags going concern risk as losses mount and Nasdaq warns

Nexalin Technology (NXL) reported significant losses and limited revenue for the quarter and six months ended June 30, 2026, leading management to conclude there is substantial doubt about its ability to continue as a going concern without additional funding. The company also faces a …

Nexalin Technology, Inc. 2Q 2026: Revenue $12.16K, EPS ($0.11) — 10-Q Summary

Nexalin Technology, Inc. reported its Q2 2026 results, showing a significant year-over-year revenue decline to $12.16K and an increased net loss of ($2.24M), resulting in a diluted EPS of ($0.11). The company saw a shift towards higher-margin licensing, improved gross margins, and made clinical …

Is Nortech Systems Inc (NSYS) Overvalued After Q2 Earnings? GF S

Nortech Systems Inc (NSYS) reported a 9.3% increase in net sales to $33.5 million for Q2 2026, alongside a slight rise in net income. Despite revenue growth, the company faces operational challenges with a 24.1% jump in operating expenses. GuruFocus assesses NSYS as overvalued …

Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall

MaxCyte reported Q2 2026 revenue of $7.3 million, exceeding analyst expectations, though shares fell after hours due to a year-over-year sales decline and lower margins. The company highlighted stabilization in the cell therapy market and a new enterprise partnership with Genentech as key developments. …

Lumexa: Q2 Earnings Snapshot

Lumexa Imaging Holdings Inc. (LMRI) reported Q2 earnings of $2.7 million, or 3 cents per share. Adjusted earnings were 20 cents per share, and revenue reached $264.2 million, exceeding analyst forecasts. The company projects full-year earnings between 71 cents and 77 cents per share, …

ClearPoint Neuro (CLPT): MAK Capital group discloses 7.8% ownership in 13G/A

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have filed a Schedule 13G/A, disclosing a collective beneficial ownership of 2,375,861 shares of ClearPoint Neuro, Inc. (CLPT) common stock. This represents 7.8% of the company's outstanding shares as of June 30, …

DexCom Inc. stock outperforms competitors on strong trading day

DexCom Inc. (DXCM) saw its stock rise by 1.42% to $90.80 on Wednesday, marking its fifth consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index increased by 0.26% and the Dow Jones Industrial Average fell by 0.04% on …

Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue

Lucid Diagnostics (LUCD) reported a 26.7% increase in Q2 2026 revenue, reaching $1.5 million, which slightly exceeded analyst expectations. Despite this top-line growth, the company continued to post significant losses, with a net loss of $14.7 million. Insider trading activity shows one purchase in …

Lumexa Imaging (NASDAQ:LMRI) Updates FY 2026 Earnings Guidance